General
Preferred name
GEPOTIDACIN
Synonyms
GSK2140944 mesylate dihydrate ()
GSK-2140944 mesylate dihydrate ()
GSK 2140944 mesylate dihydrate ()
GSK2140944 ()
Gepotidacin (mesylate hydrate) ()
Gepotidacin mesylate dihydrate ()
GEPOTIDACIN MESYLATE ()
Gepotidacine ()
GSK-2140944 ()
Gepotidacina ()
Gepotidacin mesilate dihydrate ()
GSK-2140944E ()
GSK2140944E ()
GSK-2140944 MESYLATE DIHYDRATE ()
P&D ID
PD058659
CAS
1075236-89-3
1624306-20-2
Tags
available
drug
drug candidate
Drug indication
Urinary tract infection
infection
Neisseria gonorrhoeae infection
Acute bacterial skin infection
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Gepotidacin (formerly GSK2140944) is a novel, first-in-class, triazaacenaphthylene antibacterial that inhibits bacterial DNA gyrase and topoisomerase IV via a unique mechanism . It was developed for potential to treat conventional and biothreat pathogens including MRSA, respiratory tract infections, acute bacterial skin and skin structure infections (ABSSI) , and uncomplicated urogenital gonorrhea . (GtoPdb)
DESCRIPTION Gepotidacin (GSK2140944) is a novel triazaacenaphthylene bacterial type II topoisomerase inhibitor.
DESCRIPTION Gepotidacin mesylate hydrate is an orally active triazaacenaphthylene antibiotic and bacterial type II topoisomerase inhibitor. Gepotidacin mesylate hydrate inhibits bacterial DNA replication by blocking topoisomerase enzymes. Gepotidacin mesylate hydrate selectively inhibits topoisomerase IV and the B subunit of DNA gyrase[1][2].
PRICE 659
DESCRIPTION Gepotidacin is a potent Type II DNA topoisomerase inhibitor. It is a novel antibacterial drug candidate. It is used for the treatment of gram positive bacterial infection of skin and skin structure. It is also used for the treatment of gonorrhea. It was developed by GlaxoSmithKline R & D and in clinic phase 2 trials. (BOC Sciences Bioactive Compounds)
DESCRIPTION Gepotidacin mesylate dihydrate (GSK2140944 mesylate dihydrate) is an orally available triazaacenaphthylene antibiotic with antibacterial activity. Gepotidacin mesylate dihydrate is an inhibitor of bacterial type II topoisomerase. Gepotidacin mesylate dihydrate inhibits bacterial DNA replication by blocking topoisomerase and can be used to study bacterial infection. (TargetMol Bioactive Compound Library)
Compound Sets
8
BOC Sciences Bioactive Compounds
gepotidacin-cas-1075236-89-3-item-475033
ChEMBL Drugs
CHEMBL3317856
CHEMBL3545364
Drug Repurposing Hub
DrugBank
DB12134
DrugMAP
DMSMFN2
Guide to Pharmacology
10817
MedChem Express Bioactive Compound Library
HY-16742
HY-16742B
TargetMol Bioactive Compound Library
T70358
External IDs
27
Properties
(calculated by RDKit )
Molecular Weight
448.22
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
6
Aromatic Ring Count
3
cLogP
1.09
TPSA
94.28
Fraction CSP3
0.5
Chiral centers
1.0
Largest ring
6.0
QED
0.62
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
Microbiology/virology
Anti-infection
Cell Cycle/DNA Damage
MOA
Topoisomerase inhibitor
Target
antibiotic
Bacterial
Topoisomerase
Antibacterial
Solubility
10 mM in DMSO
Source data